Top

Published in:

Open Access 22-02-2024 | Glioblastoma | Research

Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center

Authors: Melek Tugce Yilmaz, Alper Kahvecioglu, Gozde Yazici, Sepideh Mohammadipour, Neyran Kertmen, Gokcen Coban Cifci, Faruk Zorlu

Published in: Journal of Neuro-Oncology | Issue 2/2024

Abstract

Purpose

We aimed to evaluate the prognostic factors and the role of stereotactic radiotherapy (SRT) as a re-irradiation technique in the management of progressive glioblastoma.

Methods

The records of 77 previously irradiated glioblastoma patients who progressed and received second course hypofractionated SRT (1–5 fractions) between 2009 and 2022 in our department were evaluated retrospectively. Statistical Package for the Social Sciences (SPSS) version 23.0 (IBM, Armonk, NY, USA) was utilized for all statistical analyses.

Results

The median time to progression from the end of initial radiotherapy was 14 months (range, 6–68 months). The most common SRT schedule was 30 Gy (range, 18–50 Gy) in 5 fractions (range, 1–5 fractions). The median follow-up after SRT was 9 months (range, 3–80 months). One-year overall (OS) and progression-free survival (PFS) rates after SRT were 46% and 35%, respectively. Re-irradiation dose and the presence of pseudoprogression were both significant independent positive prognostic factors for both OS (p = 0.009 and p = 0.04, respectively) and PFS (p = 0.008 and p = 0.04, respectively). For PFS, progression-free interval > 14 months was also a prognostic factor (p = 0.04). The treatment was well tolerated without significant acute toxicity. During follow-up, radiation necrosis was observed in 17 patients (22%), and 14 (82%) of them were asymptomatic.

Conclusion

Hypofractionated SRT is an effective treatment approach for patients with progressive glioblastoma. Younger patients who progressed later than 14 months, received higher SRT doses, and experienced pseudoprogression following SRT had improved survival rates.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330CrossRefPubMed

Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Rudà R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170–186. https://doi.org/10.1038/s41571-020-00447-zCrossRefPubMed

Cabrera AR, Kirkpatrick JP, Fiveash JB, Shih HA, Koay EJ, Lutz S, Petit J, Chao ST, Brown PD, Vogelbaum M, Reardon DA, Chakravarti A, Wen PY, Chang E (2016) Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol 6:217–225. https://doi.org/10.1016/j.prro.2016.03.007CrossRefPubMed

Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, Cooper LAD, Malta TM, Wade TE, Sabedot TS, Brat D, Gould PV, Wöehrer A, Aldape K, Ismail A, Sivajothi SK, Barthel FP, Kim H, Kocakavuk E, Ahmed N, White K, Datta I, Moon HE, Pollock S, Goldfarb C, Lee GH, Garofano L, Anderson KJ, Nehar-Belaid D, Barnholtz-Sloan JS, Bakas S, Byrne AT, D’Angelo F, Gan HK, Khasraw M, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AME, Watts C, Weiss T, Weller M, Palucka K, Stead LF, Poisson LM, Noushmehr H, Iavarone A, Verhaak RGW (2022) Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell 185:2184-2199.e2116. https://doi.org/10.1016/j.cell.2022.04.038CrossRefPubMedPubMedCentral

De Pietro R, Zaccaro L, Marampon F, Tini P, De Felice F, Minniti G (2023) The evolving role of reirradiation in the management of recurrent brain tumors. J Neurooncol 164:271–286. https://doi.org/10.1007/s11060-023-04407-2CrossRefPubMedPubMedCentral

Minniti G, Niyazi M, Alongi F, Navarria P, Belka C (2021) Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol 16:36. https://doi.org/10.1186/s13014-021-01767-9CrossRefPubMedPubMedCentral

Martínez-Carrillo M, Tovar-Martín I, Zurita-Herrera M, Del Moral-Ávila R, Guerrero-Tejada R, Saura-Rojas E, Osorio-Ceballos JL, Arrebola-Moreno JP, Expósito-Hernández J (2014) Salvage radiosurgery for selected patients with recurrent malignant gliomas. Biomed Res Int 2014:657953. https://doi.org/10.1155/2014/657953CrossRefPubMedPubMedCentral

Minniti G, Agolli L, Falco T, Scaringi C, Lanzetta G, Caporello P, Osti MF, Esposito V, Enrici RM (2015) Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. J Neurooncol 122:559–566. https://doi.org/10.1007/s11060-015-1745-xCrossRefPubMed

Scholtyssek F, Zwiener I, Schlamann A, Seidel C, Meixensberger J, Bauer M, Hoffmann K-T, Combs SE, von Bueren AO, Kortmann R-D, Müller K (2013) Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort. Radiat Oncol 8:161. https://doi.org/10.1186/1748-717X-8-161CrossRefPubMedPubMedCentral

10.

Straube C, Elpula G, Gempt J, Gerhardt J, Bette S, Zimmer C, Schmidt-Graf F, Meyer B, Combs SE (2017) Re-irradiation after gross total resection of recurrent glioblastoma : spatial pattern of recurrence and a review of the literature as a basis for target volume definition. Strahlenther Onkol 193:897–909. https://doi.org/10.1007/s00066-017-1161-6CrossRefPubMed

11.

Combs SE, Niyazi M, Adeberg S, Bougatf N, Kaul D, Fleischmann DF, Gruen A, Fokas E, Rödel CM, Eckert F, Paulsen F, Oehlke O, Grosu A-L, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J, Kessel KA (2018) Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score—report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). Cancer Med 7:1742–1749. https://doi.org/10.1002/cam4.1425CrossRefPubMedPubMedCentral

12.

Chapman CH, Hara JH, Molinaro AM, Clarke JL, Oberheim Bush NA, Taylor JW, Butowski NA, Chang SM, Fogh SE, Sneed PK, Nakamura JL, Raleigh DR, Braunstein SE (2019) Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. Neuro-Oncol Pract 6:364–374. https://doi.org/10.1093/nop/npz017CrossRef

13.

Yazici G, Cengiz M, Ozyigit G, Eren G, Yildiz F, Akyol F, Gurkaynak M, Zorlu F (2014) Hypofractionated stereotactic reirradiation for recurrent glioblastoma. J Neurooncol 120:117–123. https://doi.org/10.1007/s11060-014-1524-0CrossRefPubMed

14.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. https://doi.org/10.1007/s00401-007-0243-4CrossRefPubMedPubMedCentral

15.

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1CrossRefPubMed

16.

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. https://doi.org/10.1200/jco.2009.26.3541CrossRefPubMed

17.

Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14:307–320. https://doi.org/10.1007/s13311-016-0507-6CrossRefPubMedPubMedCentral

18.

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106CrossRefPubMedPubMedCentral

19.

Kazmi F, Soon YY, Leong YH, Koh WY, Vellayappan B (2019) Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis. J Neurooncol 142:79–90. https://doi.org/10.1007/s11060-018-03064-0CrossRefPubMed

20.

Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, Comber E, Maltenfort M, Dicker AP, Werner-Wasik M (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053. https://doi.org/10.1200/JCO.2009.25.6941CrossRefPubMedPubMedCentral

21.

Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ Jr (1999) A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43:293–298. https://doi.org/10.1016/s0360-3016(98)00416-7CrossRefPubMed

22.

Vordermark D, Kölbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5:55. https://doi.org/10.1186/1471-2407-5-55CrossRefPubMedPubMedCentral

23.

Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Fougère C, Ertl L, Linn J, Herrlinger U, Belka C, Niyazi M (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 117:337–345. https://doi.org/10.1007/s11060-014-1394-5CrossRefPubMed

24.

Shen CJ, Kummerlowe MN, Redmond KJ, Martinez-Gutierrez JC, Usama SM, Holdhoff M, Grossman SA, Laterra JJ, Strowd RE, Kleinberg LR (2018) Re-irradiation for malignant glioma: toward patient selection and defining treatment parameters for salvage. Adv Radiat Oncol 3:582–590. https://doi.org/10.1016/j.adro.2018.06.005CrossRefPubMedPubMedCentral

25.

Ryken TC, Kalkanis SN, Buatti JM, Olson JJ (2014) The role of cytoreductive surgery in the management of progressive glioblastoma. J Neurooncol 118:479–488. https://doi.org/10.1007/s11060-013-1336-7CrossRefPubMed

26.

Navarria P, Pessina F, Clerici E, Bellu L, Franzese C, Franzini A, Simonelli M, Bello L, Santoro A, Politi LS, D’Agostino GR, Casarotti A, Fernandes B, Torri V, Scorsetti M (2022) Re-irradiation for recurrent high grade glioma (HGG) patients: results of a single arm prospective phase 2 study. Radiother Oncol 167:89–96. https://doi.org/10.1016/j.radonc.2021.12.019CrossRefPubMed

27.

Bräutigam E, Lampl C, Track C, Nieder C, Pichler J, Hammer J, Geinitz H (2019) Re-irradiation of recurrent glioblastoma as part of a sequential multimodality treatment concept. Clin Transl Oncol 21:582–587. https://doi.org/10.1007/s12094-018-1957-6CrossRefPubMed

28.

Lee J, Ahn SS, Chang JH, Suh CO (2018) Hypofractionated re-irradiation after maximal surgical resection for recurrent glioblastoma: therapeutic adequacy and its prognosticators of survival. Yonsei Med J 59:194–201. https://doi.org/10.3349/ymj.2018.59.2.194CrossRefPubMedPubMedCentral

29.

Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156–163. https://doi.org/10.1016/j.ijrobp.2008.10.043CrossRefPubMedPubMedCentral

30.

Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP (2012) Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82:2018–2024. https://doi.org/10.1016/j.ijrobp.2010.12.074CrossRefPubMed

31.

Lovo EE, Moreira A, Barahona KC, Ramirez J, Campos F, Tobar C, Caceros V, Sallabanda M, Sallabanda K (2021) Stereotactic radiosurgery for recurrent glioblastoma multiforme: a retrospective multi-institutional experience. Cureus 13:e18480. https://doi.org/10.7759/cureus.18480CrossRefPubMedPubMedCentral

32.

Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Souhami L, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M (2018) Investigating the effect of reirradiation or systemic therapy in patients with glioblastoma after tumor progression: a secondary analysis of NRG oncology/radiation therapy oncology group trial 0525. Int J Radiat Oncol Biol Phys 100:38–44. https://doi.org/10.1016/j.ijrobp.2017.08.038CrossRefPubMed

33.

Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, Huang J, Algan O, Deb N, Portelance L, Villano JL, Hamm JT, Oh KS, Ali AN, Kim MM, Lindhorst SM, Mehta MP (2023) NRG Oncology/RTOG1205: a randomized phase II Trial of concurrent bevacizumab and reirradiation versus Bevacizumab alone as treatment for recurrent glioblastoma. J Clin Oncol 41:1285–1295. https://doi.org/10.1200/JCO.22.00164CrossRefPubMed

34.

Knisely JPS, Fine HA (2023) Reirradiation for recurrent glioblastoma: what we know and what we do not. J Clin Oncol 41:1183–1188. https://doi.org/10.1200/jco.22.01785CrossRefPubMed

Title: Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center
Authors: Melek Tugce Yilmaz
Alper Kahvecioglu
Gozde Yazici
Sepideh Mohammadipour
Neyran Kertmen
Gokcen Coban Cifci
Faruk Zorlu
Publication date: 22-02-2024
Publisher: Springer US
Keywords: Glioblastoma
Glioblastoma
Glioblastoma
Radiotherapy
Bevacizumab
Published in: Journal of Neuro-Oncology / Issue 2/2024
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-024-04607-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2024

Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response

Diverse learners: learning disabilities and quality of life following mind–body and health education interventions for adults with neurofibromatosis

Correction to: Prognostic factors analysis of diffuse midline glioma

Letter to the editor: Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis

The role of spine stereotactic radiosurgery for patients with breast cancer metastases

Prognostic factors analysis of diffuse midline glioma